Articles tagged with Pancreatic Cancer
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
Researchers identified four genes - KRAS, CDKN2A, SMAD4, and TP53 - that influence pancreatic cancer survival. Patients with three or four altered genes had poorer disease-free and overall survival rates compared to those with single or dual alterations.
Research shows long-term aspirin use significantly reduces digestive cancer incidence, with substantial reductions in liver and oesophageal cancers. Aspirin use also shows promise in reducing risk of certain other cancers, while raising cardiovascular risk when stopped.
Researchers discovered a protein-cleaving enzyme called FAP that plays a role in shaping the physical nature of the stroma, promoting tumor growth and metastasis. Deleting or inhibiting FAP in mouse models of pancreatic cancer slowed disease progression and reduced cancer spread to other organs.
Researchers from four top teams receive funding to tackle cancers of the lung and pancreas using a new 'interception' approach, targeting precancerous cells before they turn into cancer cells. The initiative aims to catch cancers early, when treatment is more successful.
Pancreatic cancer is a deadly and lethal disease with an 8% 5-year relative survival rate. Researchers at UC San Diego Health, in partnership with other institutions, have received a $7 million grant to develop new ways to prevent the disease, which comprises 3% of all cancer cases but is the fourth leading cause of cancer death.
Scientists have successfully synthesized a promising anticancer molecule, BE-43547A(2), which shows unprecedented activity against pancreatic cancer stem cells. The compound reduces cancer stem cell proliferation by 21-fold and abolishes tumor-initiating capability.
The study found a near doubling of median overall survival (27.8 months) and no grade 3 or higher toxicities for patients receiving higher radiation doses with adaptive MR guided radiation therapy, compared to those receiving lower doses via non-adaptive treatments.
A new clinical trial, led by TGen's Dr. Von Hoff, will pair an immunotherapy drug with a Vitamin D Receptor agonist to treat pancreatic cancer. The study aims to remodel the tumor microenvironment and improve the delivery of immunotherapy.
Researchers at Salk Institute have discovered that modified vitamin D can reprogram the tumor environment, allowing Keytruda to invade and destroy pancreatic tumors. The clinical trial aims to combine vitamin D with immunotherapy for a potential game-changer in pancreatic cancer treatment.
A Stanford-led study discovered a specific mutation in the p53 gene that enhances its anti-tumor activity, creating a 'super tumor suppressor' that protects against pancreatic cancer. The researchers found that this mutant hyperactivates p53, leading to a surge of activity in downstream target genes.
Anti-RAS antibodies are a critical research tool, but their poor reliability limits replicable study results. Researchers identified selectively recognizing each of the four human RAS proteins only in Western blot assays.
A recent study by Tal Danino at the Data Science Institute demonstrates that bacteria in pancreatic tumors degrade a chemotherapy drug, Gemcitabine. The study found that antibiotics were effective in killing these bacteria in over 70% of mice, leading to rapid tumor progression without treatment.
A genetic test developed by UPMC scientists proved highly sensitive in detecting pancreatic cysts associated with aggressive pancreatic cancer. The test, PancreaSeq°, correctly classified patients with intraductal papillary mucinous neoplasm (IPMN) and identified cysts that would progress to cancer with 100% accuracy.
Researchers have identified a new strategy to target KRAS mutant cancer using a Galectin-3 inhibitor. The study found that binding of the protein to a specific cell surface receptor amplifies the advantages driven by mutant KRAS, creating a unique vulnerability that can be targeted with an existing drug.
A randomized clinical trial compared laparoscopic and open surgeries for pancreatic cancer patients. Laparoscopy showed reduced blood loss, decreased transfusions and shorter hospital stays without differing complications or pathological outcomes.
Researchers have identified a zinc transporter, ZIP4, that is overexpressed in pancreatic cancer cells, making it a potential target for new drugs. The study reveals the structure of ZIP4's core, which conducts zinc transport, and identifies an unprecedented fold for membrane transporters.
Researchers developed a combined 'liquid biopsy' that detected markers from both DNA and protein products of DNA, showing twice the accuracy of detection as DNA alone. The test identified early-stage pancreatic cancer in 64% of patients, improving on the 30% detection rate achieved with DNA testing alone.
A new app, BiliScreen, uses computer vision algorithms and machine learning to detect increased bilirubin levels in the eye, a potential early sign of pancreatic cancer. The app has been shown to correctly identify cases with an accuracy rate of 89.7%, offering a non-invasive and easy-to-use screening tool.
Researchers discovered that targeting arginase 2, an enzyme involved in nitrogen metabolism, can curb the growth of pancreatic tumors, especially in obese individuals. The study suggests a novel approach to treating this deadly cancer, with potential for improved survival rates and therapeutic windows.
Patients with newly diagnosed cancer face a substantially increased short-term risk of arterial thromboembolism. Lung, gastric, and pancreatic cancers are associated with the highest risk, while advanced disease increases overall tumor burden.
A study of 43 patients with pancreatic ductal adenocarcinoma found two preoperative factors strongly predictive of poor prognosis, regardless of tumor stage. These biomarkers, C-reactive protein/albumin ratio and prognostic nutritional index, may help plan treatment strategies to improve patient outcomes.
Researchers at Tokyo Medical and Dental University identified two microRNAs that can improve pancreatic cancer response to gemcitabine, a common chemotherapy drug. These findings suggest novel combined treatments for this devastating disease. MicroRNA levels can also predict prognosis in pancreatic cancer patients.
A new SU2C-Lustgarten Foundation team aims to apply CAR T-cell therapy to pancreatic cancer, a deadly form of cancer with low five-year survival rate. The team will focus on epigenetics and exploring new therapies targeting mesothelin in pancreatic cancer.
Researchers at Cold Spring Harbor Laboratory have discovered an epigenetic factor, FOXA1, that reprograms gene enhancers in cancer cells, allowing them to 'remember' an earlier developmental state and become metastatic. This mechanism is a major breakthrough in understanding the spread of pancreatic cancer.
Researchers found that inhibiting the partnership between Tregs and dendritic cells might lead to effective immunotherapy for pancreatic cancer. Blocking this relationship may enable the immune system to target pancreatic tumor cells more effectively, potentially slowing tumor growth.
A newly identified biomarker panel correctly detects early pancreatic cancer in human cells, improving the ability to diagnose patients at different stages of their disease. The panel combines plasma thrombospondin-2 with CA19-9 levels for reliable detection of pancreatic cancer, potentially altering treatment outcomes.
The Damon Runyon Cancer Research Foundation awarded $3.1M to five new Clinical Investigators and Continuation Grants to three existing recipients. The winners are conducting groundbreaking research in pancreatic cancer, glioblastoma, and leptomeningeal metastasis.
A combined molecular biology test can accurately identify benign pancreatic lesions, potentially sparing patients from unnecessary cancer screenings and operations. The test uses two proteins to rule out precancer and cancer, with a sensitivity of 95.5% and specificity of 100% for distinguishing between serous cystic neoplasms (SCN) an...
A new study demonstrates the feasibility and safety of HuMab-5B1, an antibody that targets the cancer antigen 19-9, found on pancreatic tumors and other malignancies. The treatment shows promise for better identifying tumors and directing treatment.
Researchers developed 'iExosomes' that target mutant KRAS, a common mutation in pancreatic cancer, to deliver RNAi and suppress tumor growth. The therapy approach was more efficient than traditional methods, offering new hope for treating this aggressive form of cancer.
In a Phase 2 clinical trial, adding an experimental drug to standard chemotherapy improved progression-free survival by four months in patients with metastatic pancreatic cancer and high levels of hyaluronic acid in their tumors. The results suggest the benefit of the treatment is restricted to patients with this specific biomarker.
A new study by researchers at the University of Southern California reveals that reducing glucose-regulated protein GRP78 can halt pancreatic cancer development and prolong survival. The findings suggest that targeting this protein could lead to a novel approach in treating KRAS-mutation related cancers.
Recent studies identified targeted therapies that improved benefits for patients with pancreatic cancer, including one with an ALK gene mutation. The assessment of actionable alterations is now part of routine care at UPMC.
Researchers discovered mutations in gene promoters that affect cell adhesion and axon guidance pathways in pancreatic cancer, providing new insights into its development and progression. These findings could lead to the identification of novel molecular targets for treatment.
Researchers suggest that radiotherapy could have a role in extending the lives of patients with early-stage pancreatic cancer. Studies show that higher doses of radiation are associated with longer survival times. The study analyzed data from over 500 patients and found that those who received higher doses lived significantly longer.
A new study published in the Journal of the American College of Surgeons found that pancreatic cancer patients who travel to academic medical centers for surgery have longer overall survival rates and better quality care. For thyroid cancer patients, traveling also results in more adherence to evidence-based treatment guidelines.
A new study by TGen and HonorHealth Research Institute found a very high rate of tumor shrinkage among patients with advanced pancreatic cancer when adding cisplatin to standard gemcitabine/nab-paclitaxel treatment. The results showed statistically significant improvements in overall response and survival rates.
FAU researchers identified Zeb1 as a key factor that activates embryonic programme, leading to rapid dissemination and metastasis in pancreatic cancer. They also found that blocking Zeb1 reduces metastatic capacity in other tumour types.
Researchers at NYU Langone Health have uncovered a critical pathway by which pancreatic cancer cells evade the immune system, involving high levels of two proteins - dectin-1 and galectin-9. The study found that blocking this interaction can increase survival in mice with pancreatic tumors.
Wake Forest Baptist researchers found that MIR506 inhibits malignant cell growth and metastasis in pancreatic cancer cells. The molecule induces autophagy, a process that promotes cancer cell death.
Australian scientists have discovered a novel strategy to treat pancreatic cancer by softening tumors with Fasudil before chemotherapy, doubling survival time and improving treatment efficacy. The sequential approach also slows cancer spread to other tissues.
Overall cancer death rates have decreased for 11 types of cancer in men and 13 in women between 2010-2014. Five-year survival improved significantly for prostate, kidney, non-Hodgkin lymphoma, and leukemia cancers.
Researchers at the University of Texas M. D. Anderson Cancer Center have identified arginine methyltransferase 1 (PRMT1) as a potential therapeutic target for pancreatic ductal adenocarcinoma (PDAC), a deadly form of pancreatic cancer with limited treatment options. PRMT1 plays a crucial role in tumor development and maintenance, and i...
Researchers at Tel Aviv University find that modifying specific proteins during cell division unleashes a natural killing mechanism that targets rapidly proliferating cancer cells. The discovery may lead to the development of new treatments for aggressive cancers, including pancreatic and triple negative breast cancer.
A network of clinical trials aims to find the right treatment for the right patient, using individual molecular profiles. The project will recruit 658 patients across the UK, with a focus on matching patients with suitable clinical trials already in progress.
A new optical tool uses light scattering spectroscopy to distinguish between pre-cancerous and cancerous pancreatic lesions with high accuracy. The device offers a minimally-invasive means of diagnosis, which could reduce unnecessary surgeries and improve patient outcomes.
Adding two blood-borne proteins, TFPI and tenascin C, to the current biomarker CA-19-9 improves the detection of early-stage pancreatic cancer in three cohorts. The combination shows higher predictive value than the individual biomarkers.
Researchers identified PAK1 as a key player in aggressive tumor growth, fibrosis, and chemotherapy resistance. Targeting PAK1 may increase survival rates for patients with pancreatic cancer.
Death rates from cancer are expected to decline faster in men than in women in Europe in 2017, with men predicted to fall by over 8% and women by around 4%. Lung cancer death rates will rise in women, but overall, fewer women than men will die from cancer.
A team of researchers at CIMA University has identified a new gene, FOSL1, which is critical in the development of lung and pancreatic cancers. Inhibiting this gene has been shown to drastically reduce tumor size in various experimental models.
A new study confirms PAK4's role in enabling pancreatic cancer cells to grow and spread, highlighting potential new targets for therapy. Researchers found a close relationship between PAK4 and the phosphoinositide 3-kinase pathway, which could lead to combination therapies targeting both.
A registry study of over 72,000 styrene-exposed employees found no increased incidence of common cancers such as oesophagus or lung cancer. However, a possible increased risk of myeloid leukaemia and nasal cancer was detected, highlighting the need for further investigation.
Researchers identified a gatekeeper protein SMARCB1 that prevents aggressive pancreatic cancer cells from transitioning into a resistant type. Depletion of SMARCB1 leads to mesenchymal status, a mobile and invasive cell state, making these cells vulnerable to therapies targeting proteostasis.
Researchers at Arizona State University have developed a new diagnostic method for detecting pancreatic cancer early in its development by identifying extracellular vesicles with the surface protein EphA2. This technique shows promise for rapid and sensitive detection of various diseases based on unique EV signatures.
Research found that patients diagnosed with type 2 diabetes are at increased risk of developing pancreatic cancer, particularly within the first year. The study's findings suggest a link between rapid deterioration in diabetes and early detection of pancreatic cancer.
A UK-led clinical trial has successfully prolonged survival for pancreatic cancer patients by at least five years using a combination of chemotherapy drugs. The study found that patients who received this treatment had a 29% five-year survival rate compared to 16% for those on standard treatment.
Cancer mortality in the US declined by 20.1% from 240 to 192 deaths per 100,000 population between 1980 and 2014. Distinct clusters of counties with high cancer mortality rates were found, varying by type of cancer and region.
Blocking inflammation after radiation therapy led to improved survival in a mouse model of pancreatic cancer. The study found that a form of inflammation triggered by the tumor in response to treatment helps keep tumor cells alive, and that blocking this inflammation can slow tumor growth and prolong survival.
A new standard of care for pancreatic cancer patients has been established with a combination chemotherapy treatment, doubling five-year survival rates. The treatment, combining gemcitabine and capecitabine, was found to be effective in increasing patient survival by 29% compared to single-drug therapy.
Cachexia, a condition characterized by weight loss and muscle atrophy in cancer patients, is responsible for over 30% of deaths. Researchers aim to reverse this condition through novel treatments involving febuxostat, beta-blockers, and gut microbiome transplantation.